SOM Biotech
SOM Biotech is a late-stage clinical company founded in 2010, focused on discovering and developing drugs for rare central nervous system (CNS) disorders. They utilize a proprietary Artificial Intelligence platform called SOMAIPRO®, which has demonstrated high clinical predictivity. Their lead product, SOM3355, is designed for movement and psychiatric disorders and has successfully completed Phase 2b trials in Huntington's Disease patients with chorea. SOM Biotech aims to reduce the traditional time and cost of drug development by leveraging AI, focusing on orphan diseases, and repurposing drugs. Their business model combines in-house development with external collaborations and industry partnerships.
SOM Biotech
SOM Biotech is a late-stage clinical company founded in 2010, focused on discovering and developing drugs for rare central nervous system (CNS) disorders. They utilize a proprietary Artificial Intelligence platform called SOMAIPRO®, which has demonstrated high clinical predictivity. Their lead product, SOM3355, is designed for movement and psychiatric disorders and has successfully completed Phase 2b trials in Huntington's Disease patients with chorea. SOM Biotech aims to reduce the traditional time and cost of drug development by leveraging AI, focusing on orphan diseases, and repurposing drugs. Their business model combines in-house development with external collaborations and industry partnerships.